Biosplice Announces Collaboration with Novo Nordisk in Diabetes
June 13, 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice enters into a pre-clinical collaboration with Novo Nordisk to develop inhibitors of DYRK for diabetes
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
April 18, 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Presentation of OA-07 Phase 3 Long-Term Results for Lorecivivint and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
March 08, 2024 13:36 ET
|
Biosplice Therapeutics, Inc.
Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense.
Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
December 15, 2022 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule...
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
November 17, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
September 15, 2021 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase...
Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
July 22, 2021 10:10 ET
|
Biosplice Therapeutics, Inc.
Lorecivivint post-hoc analysis reveals significantly increased likelihood of symptom improvements for knee osteoarthritis compared to placebo SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice...
Dave Johnson Joins Biosplice Therapeutics Board of Directors
June 21, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis
April 26, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea
April 22, 2021 11:36 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...